Freshfields Bruckhaus Deringer and Grandall Legal Group have advised Shanghai Pharmaceuticals Holdings Co. Ltd. on its $2 billion listing of H-shares on the Hong Kong Stock Exchange.
Shanghai Pharmaceuticals, one of China’s largest distributors of pharmaceutical products, has been listed in Shanghai since 1993. China’s H-share regime, introduced in 2007, allows mainland Chinese issuers to circumvent trading restrictions to sell stock to foreign investors on the Hong Kong exchange. The securities are regulated under Chinese rather than Hong Kong law.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
